Fenebrutinib distinguishes itself from other BTK inhibitors through its unique reversible mechanism. It aims to treat relapsing and primary progressive MS.
Fenebrutinib treatment resulted in decreased new lesion activity and enhanced penetration into the cerebrospinal fluid (CSF) in multiple sclerosis (MS) patients.
At the American Academy of Neurology conference 2024, findings from the ongoing Phase II study FENopta (NCT05119569), highlighted the efficacy and safety of fenebrutinib, a potent Bruton’s tyrosine kinase (BTK) inhibitor, in treating relapsing MS. Patients receiving fenebrutinib exhibited a significant reduction in total new T1 gadolinium-enh...